Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4284-4289

  Belema, Makonen ^a   Bunker, Amy ^a   Nguyen, Van N ^a   Beaulieu, Francis ^a   Ouellet, Carl ^a   Qiu, Yuping ^a   Zhang, Yunhui ^a   Martel, Alain ^a   Burke, James R ^a   McIntyre, Kim W ^a   Pattoli, Mark A ^a   Daloisio, Connie ^a   Gillooly, Kathleen M ^a   Clarke, Wendy J ^a   Brassil, Patrick J ^a   Zusi, F Chris ^a   Vyas, Dolatrai M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

IKK; Imidazothienopyrazine; NF B; TNF

Indexed keywords

I KAPPA B KINASE BETA; I KAPPA B KINASE BETA INHIBITOR; IMIDAZO(1,2 A)THIENO(3,2 E)PYRAZINE DERIVATIVE; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME STRUCTURE; NONHUMAN; SYNTHESIS;

ANIMALS; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; MICE; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347394507     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.031     Document Type: Article

References (28)

1. Yamamoto Y., and Gaynor R.B. Trends Biochem. Sci. 29 (2004) 72 and ref. cited therein
2. Burke J.R., Wood M.K., Ryseck R.-P., Walther S., and Meyers C.A. J. Biol. Chem. 274 (1999) 36146
3. Aupperle K.R., Bennett B.L., Han Z., Boyle D.L., Manning A.M., and Firestein G.S. J. Immunol. 166 (2001) 2705
4. For a discussion on what is termed as the classical and non-classical NF-κB signaling pathways, see:. Hoffmann A., Natoli G., and Ghosh G. Oncogene 25 (2006) 6706
5. Dejardin E. Biochem. Pharmacol. 72 (2006) 1161
6. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Nat. Rev. Drug Disc. 2 (2003) 736
7. Karin M., Yamamoto Y., and Wang Q.M. Nat. Rev. Drug Disc. 3 (2004) 17
8. Bonafoux D., Bonar S., Christine L., Clare M., Donnelly A., Guzova J., Kishore N., Lennon P., Libby A., Mathialagan S., McGhee W., Rouw S., Sommers C., Tollefson M., Tripp C., Weier R., Wolfson S., and Min Y. Bioorg. Med. Chem. Lett. 15 (2005) 2870 and ref. cited therein
9. (b) For a comprehensive review on pertinent patent literature, see:. Coish P.D.G., Wickens P.L., and Lowinger T.B. Expert Opin. Ther. Patents 16 (2006) 1
10. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., Qiu Y., and Zusi F.C. J. Biol. Chem. 278 (2003) 1450
11. McIntyre K.W., Shuster D.J., Gillooly K.M., Dambach D.M., Pattoli M.A., Lu P., Zhou X.-D., Qiu Y., Zusi F.C., and Burke J.R. Arthritis Rheum. 48 (2003) 2652
12. MacMaster J.F., Dambach D.M., Lee D.B., Berry K.K., Qiu Y., Zusi F.C., and Burke J.R. Inflamm. Res. 52 (2003) 508
13. Beaulieu F., Ouellet C., Ruediger E.H., Belema M., Qiu Y., Yang X., Banville J., Burke J.R., Gregor K.R., MacMaster J.F., Martel A., McIntyre K.W., Pattoli M.A., Zusi F.C., and Vyas D. Bioorg. Med. Chem. Lett. 17 (2007) 1233
14. It is well documented that the metabolic activation of polycyclic aromatic hydrocarbons results in electrophilic species which could alkylate proteins and DNA. For additional information, see:. Skupinska K., Misiewicz I., and Kasprzycka-Guttman T. Acta Pol. Pharm. Drug Res. 61 (2004) 233 and ref. cited therein
15. Bromochloride 3 was prepared according to the protocol described in Lumma et al. (J. Med. Chem. 1983, 26, 357) with the exception that the NCS-chlorination step was replaced with NBS-bromination and that Swern conditions were employed for the oxidation step.
16. Bradač J., Furek Z., Janežič D., Molan S., Smerkolj I., Stanovnik B., Tišler M., and Verček B. J. Org. Chem. 42 (1977) 4197
17. Meurer L.C., Tolman R.L., Chapin E.W., Saperstein R., Vicario P.P., Zrada M.M., and MacCoss M. J. Med. Chem. 26 (1992) 3845
18. Ames D.E., and Brohi M.I. J. Chem. Soc., Perkin Tans. 1 (1980) 1384
19. Ames D.E., Mitchell J.C., and Takundawa C.C. J. Chem. Res. (Miniprint) 5 (1985) 1683
20. For experimental details, see: Belema, M.; Bunker, A.; Nguyen, N.; Beaulieu, F.; Ouellet, C.; Marinier, A.; Roy, S.; Yang, X.; Qiu, Y.; Zhang, Y.; Martel, A.; Zusi, F. C. US patent 6,933,294 B2.
21. For the IKK-α and IKK-β enzyme assays, see Ref. 6a.
22. For the Jurkat cell assay, see: Burke, J. R.; Wang, S. US Patent Appl. 2005/0095616 A1.
23. The Alamar blue assay was conducted according to the protocol described in Zhi-Jun et al. (J. Immunol. Methods 1997, 210, 25) by using reagents obtained from Biosource International.
24. Although enzyme kinetics studies, described in Ref. 6a, indicated that compound 1 is probably an allosteric site inhibitor of IKK-β, the mode of action of the current class has not been elucidated. For a discussion on the role of proximal H-bond acceptor/H-bond donor moieties in determining the interaction of inhibitors with the hinge region of kinases, see:. Adams J.L., Veal J., and Shewchuk L. In: Babine R.E., and Abdel-Meguid S.S. (Eds). Protein Crystallography in Drug Discovery (2004), Wiley-VCH, Verlag GmbH & Co. KGaA: Weinheim (Chapter 2)
25. 50 ratio >10, and no compelling SAR has emerged that could explain the difference in enzyme selectivity among the various analogs. Compounds 13b, 20a, and 20h were screened against a panel of kinases (IKK-ε, p38, Her-1 and 2, LCK, EMT, VEGF, IGF-1R, and PKA) and no appreciable activities were observed (data not shown).
26. For additional PK parameters of 1, see Ref. 6a.
27. The general procedure of Ghezzi et al. (Cytokine 2000, 12, 1205), as described in Ref. 6a, was employed to evaluate the effects of compounds on LPS-induced TNF-α release in mice.
28. The PBMC assay was conducted as described by Leftheris et al. J. Med. Chem. 2004, 47, 6283.